A Double-blind Trial of Depot Corticosteroids in Behçet's Syndrome
Overview
Affiliations
Objectives: Corticosteroids are widely used in Behçet's syndrome despite the absence of controlled studies. We assessed the effect of depot corticosteroids primarily for genital ulcers and secondarily for the other mucocutaneous manifestations of Behçet's syndrome.
Methods: We randomized 86 patients who had active disease with genital ulcers to receive either intramuscular corticosteroid injections (40 mg methylprednisolone acetate) or placebo every 3 weeks for 27 weeks.
Results: Seventy-six patients (88%) completed the treatment. There were no significant differences in the mean number of genital and oral ulcers, or folliculitis between groups. The mean number of erythema nodosum lesions was less in the corticosteroid group as a whole (P = 0.0046); subgroup analyses revealed that this was significant for females (P = 0.0148) but not for males (P = 0.1).
Conclusion: Low-dose depot corticosteroids did not have any beneficial effect on genital ulcers. However, it was useful in controlling erythema nodosum lesions, especially among the females.
Soares A, Pires F, de Oliveira Quintanilha N, Santos L, Dick T, Dziedzic A Biomedicines. 2023; 11(7).
PMID: 37509521 PMC: 10377315. DOI: 10.3390/biomedicines11071882.
Kuceki G, Snyder A, Hopkins Z, Secrest A Arch Dermatol Res. 2023; 315(7):1995-2002.
PMID: 36871253 DOI: 10.1007/s00403-023-02596-4.
Kim D, Nakamura K, Kaneko F, Alpsoy E, Bang D Front Med (Lausanne). 2022; 9:987393.
PMID: 36530905 PMC: 9755684. DOI: 10.3389/fmed.2022.987393.
New insights on multigenic autoinflammatory diseases.
Efthimiou P, Petryna O, Nakasato P, Kontzias A Ther Adv Musculoskelet Dis. 2022; 14:1759720X221117880.
PMID: 36081748 PMC: 9445512. DOI: 10.1177/1759720X221117880.
Abolhasani S, Khabbazi A, Hosseini F, Gholizadeh-Ghaleh Aziz S, Alipour S Int J Ophthalmol. 2022; 15(5):813-819.
PMID: 35601158 PMC: 9091884. DOI: 10.18240/ijo.2022.05.19.